HOXA9 and breast cancer: The positive detection rates of LungMe® and OncoMe in BC were 71.5% and 92.9%, respectively, despite the observed sensitivity of an individual gene ranging between 35.7% (SHOX2) and 57.1% (RASSF1A, SEPTIN9, HOXA9).